Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Institute for OneWorld Health together with Amyris Biotechnologies has entered into an agreement with Sanofi-Aventis for the development of semisynthetic artemisinin, a key ingredient in first-line malaria treatments.
Subscribe to our email newsletter
Under the terms of the agreement, OneWorld Health, Amyris and sanofi-aventis will work jointly to develop and design pilot and commercial scale manufacturing processes, with the goal of introducing low-cost, semisynthetic artemisinin into the supply chain and artemisinin-based combination therapies (ACTs) in 2010.
Amyris will provide strain engineering expertise using the novel tools of synthetic biology. Sanofi-Aventis will provide fermentation and chemistry process development expertise, and OneWorld Health will focus on the achievement of public policy and global access goals. If technical benchmarks are achieved, sanofi-Aventis will commercialize the semisynthetic artemisinin.